These insights into the TRPV4-ADAM10-E-cadherin pathway may be confirmed in an ex vivo lung model in the future [58] and provide a basis for further research into targeted therapies for pulmonary diseases involving epithelial barrier dysfunction. Here, ADAM10 is linked to lung disorder.